ASX healthcare stocks have largely disappointed in 2026.
The S&P/ASX 200 Health Care Index (ASX: XHJ) is down more than 22% year to date.
However, one exception has been the outperformance of Tetratherix Ltd (ASX: TTX).
Image source: Getty Images
Company overview
Tetratherix engages in the development of a biostealth fluid matrix for regenerative medicine.
The firm offers Tetramatrix as its primary product. It develops a biostealth fluid matrix that evolves regenerative medicine through the use of the firm’s Tetramatrix platform technology.
Its share price has rocketed in 2026, up 42% since the start of the year.
Last week, the company released a quarterly update.
Tetratherix reported a strong quarter, highlighting progress toward commercialising its Tegenix product via a global agreement with Henry Schein and expanding into precision medicine with its STEPP drug-delivery platform, including a lucrative R&D deal with Superpower.
The company also advanced multiple clinical programs with positive tissue-healing results and expects FDA clearance for its bone regeneration technology later this year.
Morgans said the report reinforces that the ASX biotech company continues to tick off key milestones towards commercialisation.
What is Morgans’ latest view on this ASX healthcare stock?
According to Morgans, this ASX healthcare stock is making solid progress in line with previously stated timelines across each of its franchises.
We remain focused on upcoming catalysts across the four franchisees including: FDA clearance for the bone regeneration product Tegenix and TegenEOS); clinical progress for the tissue spacing products (Tutelix and Optelex) and the tissue healing products (TetraDerm); and product supply in the precision medicine franchise (STEPP).
Updated price target
In a recent note out of Morgans, the broker said it has made no changes to its forecasts.
However, it has reduced its price target to $6.84 (previously $7.03).
We maintain our SPECULATIVE BUY recommendation and expect the cadence of news flow to increase over the balance of the year.
At the time of writing, this ASX healthcare stock is trading for approximately $4.71.
Based on the updated price target from Morgans, this indicates a further upside of approximately 45%.
Foolish Takeaway
It’s worth noting that investing in biotech stocks can come with big upside, but equal risk.
Many of these types of companies are early-stage or pre-revenue, meaning their valuations often hinge on clinical trial results, regulatory approvals, or breakthrough announcements.
On the flip side, successful outcomes can lead to rapid share price appreciation, making the sector attractive to investors willing to tolerate volatility.
The key is understanding that this space is driven more by binary outcomes and sentiment than steady earnings, so diversification and careful research are essential to managing the risk/reward balance.
As Morgans correctly pointed out, FDA clearance and clinical progress will be key factors to monitor for this ASX healthcare stock.